Filters
The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in an increased risk for ischaemic optic neuropathy (ION) at 18 months when compared with the use of sodium‒glucose cotransporter-2 inhibitors (SGLT2is) and dipeptidyl peptidase-4 inhibitors (DPP4is), reports a study.
Among patients with primary membranous nephropathy, those treated with obinutuzumab are more likely to achieve complete remission than those treated with tacrolimus, according to the phase III MAJESTY trial.
In patients at high risk of bleeding who are undergoing percutaneous coronary intervention (PCI), abbreviated dual antiplatelet therapy (DAPT) durations, especially 3-month regimens, reduces bleeding events without increasing the risk of fatal or nonfatal ischaemic cardiovascular or cerebrovascular events when compared with standard DAPT durations, according to a meta-analysis.
Treatment with the thyroid hormone beta agonist resmetirom significantly improves qFibrosis continuous values (qFC), categorical stages (qFS), and individual collagen features associated with fibrosis progression at week 52 compared with placebo in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), as shown in the phase III MAESTRO-NASH trial.
Longer-term follow-up of the phase II ARTEMIS-002 trial continues to show promising efficacy of risvutatug rezetecan (ris-rez) in relapsed or refractory (R/R) sarcoma, with median overall survival (OS) reaching about 2 years, according to data presented at ESMO TAT Asia 2026.
Beta-blocker therapy following myocardial infarction (MI) reduces the risk of death in patients with comorbid chronic obstructive pulmonary disease (COPD), with the magnitude of benefit similar to that observed in patients without COPD, according to a Danish cohort study.
Treatment with either low- or high-dose vedolizumab yields high rates of clinical remission in children with moderate-to-severe ulcerative colitis (UC), regardless of weight, according to the phase III KEPLER trial presented at ESPGHAN 2026.
Treatment with hydroxychloroquine does not appear to improve the chances of livebirth for women with a history of three consecutive miscarriages, according to a phase III study.
Upadacitinib demonstrates its noninferiority to tofacitinib in improving lung transplantation-free survival (LTFS) at 6 months among patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease (MDA5+DM-ILD), reports a study.
Statin use may reduce the risk of cancer at several sites, including the liver, lung, colon, and rectum, especially for individuals with diabetes, as shown in a retrospective study.
